# Neuble AI Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuble-ai-co

- Industry: Software
- Headquarters: Seoul, South Korea
- Website: www.neubleai.com/
- Total disclosed funding: $0.3M
- Latest round: Seed (Jul 16, 2026)
- Investors on record: 1

## About

Based in South Korea, Neuble AI Co., Ltd. develops advanced medical AI solutions that enhance CT imaging capabilities, aiming to provide efficient brain diagnostics comparable to MRI technology.Neuble AI Co., Ltd. is focused on integrating artificial intelligence with computed tomography to improve diagnostic accuracy. Founded in 2025 in Seoul, South Korea, the company has completed 1 deal, with the latest funding round in July 2026 resulting in KRW 400 million raised through a Seed round led by FuturePlay. The company has not undergone any significant operational pivots or changes in strategy since its establishment.Neuble specializes in advanced medical AI solutions that integrate artificial intelligence with computed tomography (CT) imaging to deliver brain information with precision comparable to magnetic resonance imaging (MRI). The company’s core offerings focus on enhancing the diagnostic capabilities of CT scans, aiming to provide detailed, high-resolution brain analysis in a fraction of the time traditionally required for MRI scans. These products target healthcare institutions and radiology centers seeking efficient diagnostic tools that improve patient outcomes by reducing wait times and increasing diagnostic accuracy. Neuble’s services are primarily marketed in North America and select markets in Europe, where there is a strong demand for innovative medical imaging solutions that address the need for rapid and reliable brain diagnostics.Neuble generates revenue through direct sales of its AI-enhanced CT imaging solutions and associated software services to healthcare providers. Transactions typically occur on a business-to-business (B2B) model, where hospitals and clinics purchase the technology as part of their diagnostic imaging offerings. This may involve one-time purchases or subscription-based models for ongoing access to software updates and support services. The flagship product, which integrates AI capabilities into standard CT imaging equipment, is expected to attract significant interest due to its potential to streamline diagnostic processes and improve clinical decision-making. Pricing structures are based on the scale of deployment and the specific needs of clients, allowing for tailored agreements that meet varying healthcare demands.In July 2026, Neuble AI Co., Ltd. raised KRW 400 million in Seed funding led by FuturePlay. The company will utilize this funding to pursue domestic and international medical device approvals for the commercialization of BrainCura, expand proof of concept targeting health checkup centers, enhance the artificial intelligence model, and recruit specialized personnel.

## Funding rounds

- Seed, Jul 16, 2026, $0.3M — FuturePlay

## Investors

- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Seed